Ark plant receives approval

The Finnish Medicines Agency (FIMEA) has extended Ark Therapeutics' GMP certification to include its newest and largest production facility in Kuopio, Finland. The 650m² facility has been designed for larger scale production from suspension cell cultures utilising state-of-the-art single use systems and includes an automated fill and finish line capable.
Ark Therapeutics

Strongest Q for SAFC

In its strongest quarter ever, SAFC reported sales of $197m in Q1 2012. The company said the organic sales growth rate for SAFC in the first quarter was in the low single digits but it expects sales growth to move from low-mid single digits in the first half of the year to low double digits for the second half.
Seeking Alpha

The US FDA has approved Codexis' manufacturing process for sitagliptin the API in Merck's diabetes drug Januvia

Bloomberg BusinessWeek

Dalton Pharma Services will manufacture an antiviral agent developed by Defence Research and Development Canada

Dalton Pharma

Albemarle reposted Q1 2012 sales of $190m for its fine chemicals business, up 7% on 2011 and income of $39 million, up 31%

Seeking Alpha

Kemwell Biopharma has added a 750m2 cGMP pilot plant at its Bangalore, India facility

Outsourcing Pharma

AMRI will develop and manufacture Biota Holdings influenza antiviral CS8958

Albany Times-Union

£800k deal for Angel

Angel Biotechnology will develop and manufacture a recombinant interferon product for TransGenRx at its Cranlingon, UK, faulty. As part of the £800,000 deal Angel will work to attain acceptable expression levels on which to establish a GMP manufacturing process, which would then be conducted by Angel.
Angel Biotechnology

Helsinn's Biasca, Switzerland, facility underwent a successful FDA inspection for the production of APIs and HPAPIs

CheManager

Aesica's Queenborough, UK, site has passed an FDA inspection for the production of solid dosage forms

Manufacturing Chemist

Lonza will manufacture Agennix’s dendritic cell mediated immunotherapy, talactoferrin, at its microbial manufacturing facility in Kouřim, Czech Republic

Pharmaceutical Business Review

Lonza will perform process development for Immutep's lead clinical development-stage cancer therapy

Genetic Engineering and Biotechnology News

Avecia Biotechnology has changed its name to Nitto Denko Avecia

Avecia

Merck and Codexis have developed an efficient, enzyme-based production method for a key intermediate in the production of boceprevir

InPharm

Lonza has appointed Richard Ridinger as its new chief executive officer

Bloomberg

Sigma-Aldrich acquires Research Organics

Sigma-Aldrich has acquired Research Organics, Inc. to expand its buffer production capacity and to increase its portfolio of raw materials for the biopharmaceutical and diagnostic markets. Sigma-Aldrich will merge Research Organics into its SAFC business unit.
St Louis Business Journal

CIA seeks companies for UK pavilion at CPhI

The UK's Chemical Industries Association is seeking expressions of interest from UK-based companies offering products and services within the fine chemical industry interested in exhibiting on a UK pavilion at CPhI in Madrid, Spain, during October.
For more information contact CIA

Dottikon has established a US subsidiary Dottikon ES America Inc to meet US business development requirements

Dottikon

Fujifilm Diosynth Biotechnologies expands R&D capabilities

Fujifilm Diosynth Biotechnologies has completed the first phase of a £3m investment in new equipment and laboratories at its Billingham, UK site. The company has refitted its microbial fermentation laboratory to including eight new in-situ sterilisable 20L fermenters and a number of bench-top high-throughput units. Additionally, the company has added a new suite of R&D laboratories for process development work and plans to further additions in Billingham and at its North Carolina site.
Contract Pharma